Cargando…

Comparison between coagulation factor VIII quantified with one‐stage activity assay and with mass spectrometry in haemophilia A patients: Proof of principle

INTRODUCTION: Haemophilia A is a hereditary bleeding disorder caused by a factor VIII (FVIII) deficiency. As biomarker, FVIII activity is used to classify disease severity and to monitor treatment. The one‐stage clotting assay (OSA) is performed to measure FVIII activity, but OSA's limitations...

Descripción completa

Detalles Bibliográficos
Autores principales:	Donners, Anouk A. M. T., van Maarseveen, Erik M., Weetink, Yrea R. J., El Amrani, Mohsin, Fischer, Kathelijn, Rademaker, Carin M. A., Egberts, Toine C. G., Huisman, Albert, Musson, Ruben E. A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	ORIGINAL ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754357/ https://www.ncbi.nlm.nih.gov/pubmed/32633067 http://dx.doi.org/10.1111/ijlh.13283

Ejemplares similares

The efficacy of the entire-vial dosing of emicizumab: Real-world evidence on plasma concentrations, bleeds, and drug waste
por: Donners, Anouk A.M.T., et al.
Publicado: (2023)

Pharmacokinetics and Associated Efficacy of Emicizumab in Humans: A Systematic Review
por: Donners, Anouk A. M. T., et al.
Publicado: (2021)

Quantification of emicizumab by mass spectrometry in plasma of people with hemophilia A: A method validation study
por: Donners, Anouk A. M. T., et al.
Publicado: (2022)

Factor VIII companion diagnostic for haemophilia
por: Hu, Chunxiao, et al.
Publicado: (2022)

DosEmi study protocol: a phase IV, multicentre, open-label, crossover study to evaluate non-inferiority of pharmacokinetic-guided reduced dosing compared with conventional dosing of emicizumab in people with haemophilia A
por: Donners, Anouk, et al.
Publicado: (2023)

PROTECT VIII Kids: BAY 94‐9027 (PEGylated Recombinant Factor VIII) safety and efficacy in previously treated children with severe haemophilia A
por: Santagostino, Elena, et al.
Publicado: (2020)

Recombinant factor VIII Fc for the treatment of haemophilia A
por: Hermans, Cedric, et al.
Publicado: (2021)

Long-Term Melatonin Therapy for Adolescents and Young Adults with Chronic Sleep Onset Insomnia and Late Melatonin Onset: Evaluation of Sleep Quality, Chronotype, and Lifestyle Factors Compared to Age-Related Randomly Selected Population Cohorts
por: Zwart, Tom C., et al.
Publicado: (2018)

Biological mechanisms underlying inter‐individual variation in factor VIII clearance in haemophilia
por: Turecek, Peter L., et al.
Publicado: (2020)

Treatment and Prevention of Bleeds in Haemophilia Patients with Inhibitors to Factor VIII/IX
por: Rocino, Angiola, et al.
Publicado: (2017)

Impact of extreme weight loss on factor VIII concentrate pharmacokinetics in haemophilia
por: van Moort, Iris, et al.
Publicado: (2021)

Safe and effective pharmacotherapy in infants and preschool children: importance of formulation aspects
por: van Riet-Nales, Diana A, et al.
Publicado: (2016)

Platelet-targeted gene therapy with human factor VIII establishes haemostasis in dogs with haemophilia A
por: Du, Lily M., et al.
Publicado: (2013)

PROTECT VIII kids extension study: Long‐term safety and efficacy of BAY 94‐9027 (damoctocog alfa pegol) in children with severe haemophilia A
por: Mancuso, Maria Elisa, et al.
Publicado: (2021)

Identification of a novel mutation in the factor VIII gene causing severe haemophilia A
por: Nissen, S. K., et al.
Publicado: (2018)

Measurement of joint health in persons with haemophilia: A systematic review of the measurement properties of haemophilia‐specific instruments
por: Gouw, Samantha C., et al.
Publicado: (2018)

Quantification of neutralizing anti-drug antibodies and their neutralizing capacity using competitive displacement and tandem mass spectrometry: Infliximab as proof of principle
por: El Amrani, Mohsin, et al.
Publicado: (2019)

Dosing of factor VIII concentrate by ideal body weight is more accurate in overweight and obese haemophilia A patients
por: van Moort, Iris, et al.
Publicado: (2020)

Area under the curve: Comparing the value of factor VIII replacement therapies in haemophilia A
por: Persson, Sofie, et al.
Publicado: (2022)

Ex vivo factor VIII‐modified proliferating human hepatocytes therapy for haemophilia A
por: Zhang, Kun, et al.
Publicado: (2023)

Development and Characterization of Recombinant Ovine Coagulation Factor VIII
por: Zakas, Philip M., et al.
Publicado: (2012)

FACTOR VIII COAGULANT ACTIVITY AND FACTOR VIII-LIKE ANTIGEN: INDEPENDENT MOLECULAR ENTITIES
por: Zimmerman, Theodore S., et al.
Publicado: (1973)

Combining factor VIII levels and thrombin/plasmin generation: A population pharmacokinetic‐pharmacodynamic model for patients with haemophilia A
por: Bukkems, Laura H., et al.
Publicado: (2022)

Clinical Application of Factor VIII:C to VWF:Ag Ratio for the Screening of Haemophilia A Carriers
por: Yoo, Ki-Young, et al.
Publicado: (2022)

Italian experience with rVIII-single chain: a survey of patients with haemophilia A and their physicians
por: Borchiellini, Alessandra, et al.
Publicado: (2021)

Sports participation and sports injuries in Dutch boys with haemophilia
por: Versloot, Olav, et al.
Publicado: (2020)

Bacterial Production of Recombinant Coagulation Factor VIII Domains
por: Bashar, Saima, et al.
Publicado: (2023)

Assessing the test–retest reliability and smallest detectable change of the Haemophilia Activities List
por: Kuijlaars, Isolde A. R., et al.
Publicado: (2020)

Successful Long Term Eradication of Factor VIII Inhibitor in Patients with Acquired Haemophilia A in Saudi Arabia
por: Zaher, Galila, et al.
Publicado: (2012)

Successful transfemoral prosthesis in a patient with haemophilia A and factor VIII inhibitors: A case report
por: Chao, Ta-Chung, et al.
Publicado: (2023)

Associations Between Late-Onset Preeclampsia and the Use of Calcium-Based Antacids and Proton Pump Inhibitors During Pregnancy: A Prospective Cohort Study
por: van Gelder, Marleen M H J, et al.
Publicado: (2022)

Oral Medicines for Children in the European Paediatric Investigation Plans
por: van Riet – Nales, Diana A., et al.
Publicado: (2014)

Human coagulation factor VIII domain-specific recombinant polypeptide expression
por: Choi, Su Jin, et al.
Publicado: (2015)

Does difference between label and actual potency of factor VIII concentrate affect pharmacokinetic‐guided dosing of replacement therapy in haemophilia A?
por: Goedhart, Tine M.H.J., et al.
Publicado: (2022)

Red Blood Cells are Appropriate Carrier for Coagulation Factor VIII
por: Sayyadipour, Fatemeh, et al.
Publicado: (2020)

Identification of Key Coagulation Activity Determining Elements in Canine Factor VIII
por: Firrman, Jenni, et al.
Publicado: (2020)

Hæmophilia
por: Porter, Charles A.
Publicado: (1900)

Long‐term joint outcomes in adolescents with moderate or severe haemophilia A
por: Schmidt, David E., et al.
Publicado: (2022)

Zero incidence of factor VIII inhibitors and successful haemostatic response in previously factor VIII‐treated patients with haemophilia A switching to turoctocog alfa in a noninterventional study
por: Escuriola Ettingshausen, Carmen, et al.
Publicado: (2021)

A qualitative study on the experiences of haemophilia carriers before, during and after pregnancy
por: Punt, Marieke C., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tvcp4il2foj8c9p32k2qlbc77u